Table of Contents

1 Traceability .............................................................................................................3
2 Essential Elements of Traceability .................................................................5
3 About ICCBBA.......................................................................................................8
1 Traceability

In the field of medical products of human origin (MPHO) traceability is the ability to bi-directionally track from a donor to recipient, and from the recipient back to the donor. Traceability is recognized as an essential feature of the safe use of MPHO and is a regulatory requirement in many countries.

Effective traceability is essential to support hemovigilance and biovigilance systems, and for the follow-up of MPHO in the event of product recall or lookback. Delay in the tracking of all products associated with an adverse event can result in unsafe product being clinically applied, or in patients who have already received such products failing to receive timely remedial treatment.

Regulations require that traceability exists between donor and recipient, and can be followed in both directions (i.e. Lookback - track from donor to recipient, and Traceback - track from recipient to donor). However, compliance with such regulation alone may not provide a sufficiently effective traceability system to satisfy patient safety needs. Regulatory requirements for traceability may not include:

- tracking of other products derived from the same donor at the same time (e.g. tissue traceability regulation does not require tracing of organs procured at the same time as the tissue);
- the need to trace other products from the same donor given at different points in time (e.g. previous and subsequent blood donations);
- the need to trace products from individuals who may provide multiple types of MPHO over a period of time (e.g. a blood donor may also be a sperm donor);
- mechanisms to ensure that the traceability path remains intact across organizational and national boundaries (Regulation generally places traceability requirements on individual organizations but does not explicitly recognize that the traceability path crosses organizational boundaries and that these boundaries have to be actively managed);
- any requirement for the timeliness of traceability;
• a requirement for end-to-end audit of traceability on a regular basis.

As a result, the quality of traceability systems varies widely. In all but the most advanced systems, traceback and lookback actions tend to be complex, slow and often incomplete. This is well illustrated in a US CDC report (Morbidity and Mortality Weekly Report, Dec 23, 2011) that dealt with the transmission of Hepatitis C virus through transplanted organs and tissues. The authors noted: “The events in this report demonstrate the importance of timely communication once a transplant transmission is suspected and the difficulty of tracking tissue to the patient or provider level should a potential transmission be recognized after tissue has been distributed.”

The challenges for regulators are:

• In many cases the underlying legislation on which regulation is developed deals with specific types of MPHO product causing fragmentation of the responsibility across regulatory bodies.

• Regulation is applied to individual organizations, but the traceability path crosses organizational, and sometimes regulatory, boundaries and responsibility for managing the traceability interface is not well defined.

• Regulation applies within specific boundaries (state, country, region) but products may move across these boundaries.
2 Essential Elements of Traceability

In order to provide effective traceability there are several information management requirements that need to be met. These include: unique identification; accurate data capture and transfer; and, comprehensive records with effective security, and robust data retention and retrieval. These requirements need to be managed within a quality management system and subject to regular audit. Each of these aspects is described in more detail below.

Unique Identification

The need for unique or distinct identifiers for donors and donation events is widely recognized and required by regulation. However, the term unique on its own is ambiguous if not associated with a domain within which uniqueness is required. Thus, a hospital number is unique within a hospital but may not be so in the wider healthcare community, a social security number is unique within a country but may not be so internationally. To support traceability, unique identification needs to be established across the domain of use. Regulatory requirements for unique identification of products can be satisfied within the national domain but MPHO move across national boundaries and so have an international domain. For this reason, it is important to adopt an identification system that can provide globally unique identifiers with uniqueness guaranteed for the lifetime of all products. The system should also ensure that MPHO identifiers cannot be confused with identifiers used in other areas of informatics. ISBT 128 provides such a system with identifiers that are unique over a 100-year period, and with data identifiers that are reserved for ISBT 128 usage.

Accurate Data Capture and Transfer

Traceability depends on an unbroken chain of information between the donation event and the clinical application of MPHO. Errors in the recording or transfer of key identifiers can cause breaks in the chain making traceability difficult and sometimes impossible. Manual transcription is prone to particular types of error including transposition and omission of characters. To prevent this, a checksum can be used. The checksum is an additional one or two characters added to the identifier that is printed alongside the human readable form of the identifier, and is included in manual data entry. The checksum is calculated from the identifier, and receiving systems can re-calculate the checksum to ensure it is identical to that entered. A difference indicates
that the user has made an error in data entry. Checksums have to be specifically designed to detect the most common types of human error and there are ISO Standards defining them.

Modern bar codes used for electronic data capture have their own in-built checksum systems and errors are extremely rare. However, it is important to ensure that label printers are in good condition and that labels are regularly validated.

Accuracy of data also includes the need to ensure that coded information is interpreted consistently by both the sender and receiver of the information. For this reason, ISBT 128 provides internationally standardized terminology for product descriptions, and reference tables associated with other specific pieces of critical information to ensure a common understanding.

**Comprehensive Records**

Traceability depends on records that maintain an unbroken chain of information. Every organization involved in the handling of MPHO products from donation through to clinical application has a responsibility to retain comprehensive traceability records, covering the segment of the traceability pathway that they are responsible for, that can be readily searched. These records need to carry the unique identifiers for the MPHO product (donation number, product identifier and division number) and include information about the source of the MPHO (donor information for collection facilities, or the providing organization for facilities further down the chain), and the destination (facility the product was transferred to, or patient information of the organization responsible for clinical application.) If there is any change in identifiers (e.g. a new donation number issued to identify a pooled product) then records need
to be maintained to provide a bi-directional link between the old and new identifiers.

Records need to be secure and meet applicable privacy and confidentiality regulation, particularly if they contain personal information. They also need to be securely stored in a manner that prevents their degradation. MPHO records need to be retained for long periods in order to satisfy regulation and this means record retention has to be actively managed. Manual (paper) records need to be stored in an environment that prevents their physical deterioration and ensures their security. Paper and inks need to be validated to ensure that they will not fade significantly over time. Electronic records need to be managed to ensure that they remain accessible as technology develops. This may require records to be transferred to newer forms of media during their lifetime.

Quality System and Audit

Records need to be managed according to strict procedures as part of the quality management system of the organization. Regular audit should be performed and this should include testing of records spread across the storage lifetime. Older records are more prone to loss or deterioration and this should be prevented by active assessment and management.
3 About ICCBBA

ICCBBA is the not-for-profit standards body responsible for the management, development, and distribution of the ISBT 128 Standard. It maintains a permanent office to manage the registration of facilities, update reference tables and databases, and develop additional functionality. It supports Technical Advisory Groups that include experts from both the transfusion/transplantation community and relevant manufacturers. Fees collected by ICCBBA from registered facilities are used to support these functions.

Through its activities ICCBBA provides the management support to sustain the standardization of information essential to support traceability in the complex MPHO environment. In particular it delivers:

1) Stability – users can be confident in the stability of the standard to satisfy the long time periods over which information has to be retained;
2) User focus – the user community are the experts in their field and ICCBBA, through its Technical Advisory Groups, ensures that the information standard meets, rather than dictates, user needs;
3) Flexibility – as clinical and scientific knowledge grows there is rapid development with changing information needs. ICCBBA ensures that the standard is flexible enough to accommodate those needs;
4) Responsiveness – in these rapidly developing medical fields ICCBBA ensures that the standard is able to respond to user needs in a timely manner;
5) Globalization – ISBT 128 is a truly international standard with endorsement worldwide;
6) Compatibility – standards do not work in isolation but need to interface with equipment, software, and other standards. ICCBBA works with industry and other standards bodies to maximize compatibility.
Blood, cellular therapy, tissue, organ, and banked human milk collection facilities, and manufacturers of equipment or software that uses ISBT 128, are required to register with ICCBBA and pay a registration fee and an annual, activity based, licensing fee. Registered organizations obtain access to all ICCBBA documents and databases.

For further information on ISBT 128, visit the ICCBBA website at www.iccbba.org or call us at +1 909 793 6516
Editor:
Paul Ashford, MSc. CEng. CSci.
Executive Director
ICCBBA

Standards Committee

John Armitage, Prof., BSc, PhD United Kingdom
Paul Ashford, MSc. CEng. CSci. ICCBBA
Wayne Bolton, B.App.Sc., M.App.Sc Australia
Suzanne Butch, MA, MT(ASCP)SBB United States of America
Jørgen Georgsen, MD Denmark
Karen Moniz, MHA, MT(ASCP)SBB ICCBBA
Mario Muon, MD Portugal
Stefan Poniatowski, BSc, MIBMS Australia
Leigh Sims Poston, BS, MT(ASCP) United States of America
Ineke Slaper-Cortenbach, PhD The Netherlands
Zbigniew Szczepiorkowski, MD, PhD, FCAP United States of America
Izabela Uhrynowska-Tyszkiewicz, MD, PhD Poland

Published by:
ICCBBA
PO Box 11309, San Bernardino, CA 92423-1309 USA
www.iccbba.org
Copyright, Warranty, and Liability Notice

Copyright 2020. ISBT 128 is not in the public domain and is protected by law. Implementation of ISBT 128 requires the end-user to register with ICCBBA and to pay an annual license fee. License fees are established by the ICCBBA Board of Directors to cover the expenses of maintaining and extending ISBT 128, and making available current versions of documents and database tables.

Any use of this document, or the accompanying database tables, by other than registered organizations, or facilities that have obtained their computer software from a registered and licensed developer, is strictly forbidden. Copying any portion of the Standard, or of any accompanying database table, either in electronic or other format, without express written permission from ICCBBA is strictly forbidden. Posting of any portion of the Standard, or of any accompanying database tables, to any online service by anyone other than ICCBBA is strictly forbidden.

ICCBBA provides no representation or warranty that the Licensee’s use of ISBT 128 is suitable for any particular purpose and the selection, use, efficiency and suitability of ISBT 128 is the sole responsibility of the Licensee.

ICCBBA’s liability is limited to that specified in the ICCBBA License Agreement which is available on the ICCBBA website. Under no circumstances shall ICCBBA’s liability to licensee or any third party under any theory or cause of action exceed the current annual license fee payable by the licensee to ICCBBA hereunder, and ICCBBA will in no circumstances be liable for any direct or indirect damages whatsoever, including without limitation special, incidental, consequential, or punitive damages or damages for loss of data, business or goodwill or any other consequential losses of any nature arising from the use of ISBT 128 or the marks.

This document may be translated, without written permission, provided that the translation indicates that it is a translation from an ICCBBA copyrighted document and that ICCBBA is not responsible for the accuracy of the translation.